Migraines

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17. The trial met its primary endpoint with Ajovy...

This article was originally published on Cannabis.net and appears here with permission. Migraine sufferers drop prescription drugs at record pace and switch to cannabis for headache pain! Ask anyone who’s ever suffered from chronic migraines, and they can tell you that these headaches...

This article was originally published on The Fresh Toast and appears here with permission. Studies report marijuana can reduce headache and migraine severity, but exact doses currently remain unknown. Unless you experience a headache, and especially a migraine, you have no idea how disabling they...

Medical marijuana, hemp and CBD have begun to receive increasingly serious consideration as viable medical alternatives, though research on cannabis’s impact on migraine headaches has been limited - that is until a group of headache experts all gathered in one spot. The 2023...

AbbVie Inc (NYSE: ABBV) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the preventive treatment of chronic migraine in adults. The trial met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to...

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its primary endpoints in a Phase 3 trial. The drug, zavegepant, a small-molecule CGRP receptor that can work as a spray...

The FDA has signed off Tonix Pharmaceuticals Holding Corp's (NASDAQ: TNXP) Investigational New Drug (IND) Application to initiate Phase 2 study of TNX-1900 for migraine.  TNX-1900 is intranasal potentiated oxytocin designed for the prevention of migraine headaches in...

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S. Rimegepant is commercialized as Nurtec ODT in the U.S. and is indicated for the acute treatment of migraine attacks with or...

The FDA has approved AbbVie Inc's (NYSE: ABBV) Qulipta (atogepant) to prevent episodic migraines in adults. Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for the preventive treatment of migraine. Qulipta will...

Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimegepant) orally disintegrating tablet (ODT) patients take every other...

The FDA has approved Biohaven Pharmaceutical Holding Co Ltd’s (NYSE: BHVN) dissolvable, Nurtec ODT (rimegepant), for preventive treatment in people who experience episodic migraines or fewer than 15 days of headaches per month. The move makes Nurtec ODT the first oral anti-...

Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA) — has struggled amid sagging sales of its blockbuster multiple sclerosis treatment Capaxone due to a generic launch in 2017 and its debt burden following the purchase of Allergan plc (NYSE: AGN)'s generic unit — has...